{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:54:39Z","timestamp":1790830479585,"version":"4.1.0"},"reference-count":235,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ymthe.2022.01.034","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T05:00:41Z","timestamp":1643605241000},"page":"1822-1849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Adenovirus-based vaccines\u2014a platform for pandemic preparedness against emerging viral pathogens"],"prefix":"10.1016","volume":"30","author":[{"given":"Lynda","family":"Coughlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-9007","authenticated-orcid":false,"given":"Dmitry M.","family":"Shayakhmetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.01.034_bib1","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2022.01.034_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.idc.2015.08.001","article-title":"Measles 50 years after use of measles vaccine","volume":"29","author":"Goodson","year":"2015","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.ymthe.2022.01.034_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/jpgm.JPGM_508_18","article-title":"Worldwide trend in measles incidence from 1980 to 2016: a pooled analysis of evidence from 194 WHO member states","volume":"65","author":"Krishnamoorthy","year":"2019","journal-title":"J.\u00a0Postgrad. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in\u00a0vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in\u00a0vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.01.034_bib6","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.01.034_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection","volume":"19","author":"Henry Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.01.034_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41467-017-00928-3","article-title":"Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice","volume":"8","author":"He","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.01.034_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.01.034_bib10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2010-03-272336","article-title":"CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells","volume":"117","author":"Bassett","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.01.034_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1201-9712(98)90096-0","article-title":"The myth of the medical breakthrough: smallpox, vaccination, and Jenner reconsidered","volume":"3","author":"Gross","year":"1998","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib13","first-page":"21","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib14","doi-asserted-by":"crossref","first-page":"607333","DOI":"10.3389\/fimmu.2020.607333","article-title":"Adenoviral vectors as vaccines for emerging avian influenza viruses","volume":"11","author":"Kerstetter","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib15","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1016\/j.vaccine.2007.07.030","article-title":"Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases","volume":"25","author":"Kitchen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib16","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.vaccine.2012.12.029","article-title":"History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (adenovirus vaccine) in the context of the department of defense acquisition system","volume":"31","author":"Hoke","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib17","first-page":"185","article-title":"Control of adenovirus acute respiratory disease in U.S. army trainees","volume":"48","author":"Top","year":"1975","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib19","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1016\/j.vaccine.2019.08.087","article-title":"Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the vaccine adverse event reporting system (VAERS), United States, October 2011-July 2018","volume":"37","author":"McNeil","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib20","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.vaccine.2013.04.035","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits","volume":"31","author":"Kuschner","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib21","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1016\/j.vaccine.2021.05.065","article-title":"Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells","volume":"39","author":"Shingai","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nri2054","article-title":"Scientific barriers to developing vaccines against avian influenza viruses","volume":"7","author":"Subbarao","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.01.034_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.80.1.1","article-title":"Expression of hepatitis B surface antigen gene in yeast","volume":"80","author":"Miyanohara","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.01.034_bib25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.vaccine.2013.11.036","article-title":"One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge","volume":"32","author":"Klausberger","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2010.05.034","article-title":"Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles","volume":"405","author":"Song","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2022.01.034_bib28","doi-asserted-by":"crossref","first-page":"564627","DOI":"10.3389\/fimmu.2020.564627","article-title":"Chimeric virus-like particles and capsomeres induce similar CD8(+) T\u00a0cell responses but differ in capacity to induce CD4(+) T\u00a0cell responses and antibody responses","volume":"11","author":"Pattinson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1365-2222.2011.03783.x","article-title":"Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study","volume":"41","author":"Klimek","year":"2011","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ymthe.2022.01.034_bib30","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1073\/pnas.94.14.7503","article-title":"Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T\u00a0cells","volume":"94","author":"Sedlik","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.01.034_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.virol.2018.08.019","article-title":"Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine","volume":"524","author":"Kim","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2022.01.034_bib32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/icb.2010.161","article-title":"Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway","volume":"89","author":"Win","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI28607","article-title":"Prophylactic human papillomavirus vaccines","volume":"116","author":"Lowy","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.01.034_bib34","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57659","article-title":"Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens","volume":"9","author":"Ueda","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2022.01.034_bib35","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","article-title":"Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines","volume":"184","author":"Walls","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.01.034_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41541-021-00392-7","article-title":"A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge","volume":"6","author":"Wuertz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1591","article-title":"Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates","volume":"7","author":"He","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.01.034_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe5449","article-title":"Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates","volume":"13","author":"Darricarrere","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.01.034_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.01.034_bib41","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-20-0061","article-title":"A DNA-launched nanoparticle vaccine elicits CD8(+) T-cell immunity to promote in\u00a0vivo tumor control","volume":"8","author":"Xu","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2022.01.034_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/v13020270","article-title":"Synthetic messenger RNA-based vaccines: from scorn to hype","volume":"13","author":"Pascolo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2022.01.034_bib43","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1128\/JVI.00593-09","article-title":"Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus","volume":"83","author":"Finn","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.tibtech.2013.06.001","article-title":"Marker-free plasmids for biotechnological applications - implications and perspectives","volume":"31","author":"Oliveira","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-middle east respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib46","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib47","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-zika virus DNA vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/v12121351","article-title":"Adenovirus-extracellular protein interactions and their impact on innate immune responses by human mononuclear phagocytes","volume":"12","author":"Cheneau","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2022.01.034_bib49","doi-asserted-by":"crossref","first-page":"685218","DOI":"10.3389\/fimmu.2021.685218","article-title":"Lactoferrin retargets human adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human phagocytes","volume":"12","author":"Cheneau","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib50","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.1226625","article-title":"Coagulation factor X activates innate immunity to human species C adenovirus","volume":"338","author":"Doronin","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.01.034_bib51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.01.034_bib52","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.01.034_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/biol.1995.0025","article-title":"Recombinant adenoviruses as vaccines","volume":"23","author":"Randrianarison-Jewtoukoff","year":"1995","journal-title":"Biologicals"},{"key":"10.1016\/j.ymthe.2022.01.034_bib54","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1099\/0022-1317-71-10-2425","article-title":"Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine","volume":"71","author":"Eloit","year":"1990","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib55","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.01.034_bib56","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib57","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an ad26-vectored anti-zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib60","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.chom.2021.08.002","article-title":"An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates","volume":"29","author":"Zabaleta","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.01.034_bib61","article-title":"Self-replicating RNA viruses for vaccine development against infectious diseases and cancer","volume":"9","author":"Lundstrom","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib63","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib64","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1038\/s41467-021-26499-y","article-title":"A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses","volume":"12","author":"Sun","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.01.034_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.791764","article-title":"Safety and immunogenicity analysis of a Newcastle disease virus (NDV-HXP-S) expressing the spike protein of SARS-CoV-2 in sprague dawley rats","volume":"12","author":"Tcheou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib66","doi-asserted-by":"crossref","first-page":"103379","DOI":"10.1016\/j.isci.2021.103379","article-title":"Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2","author":"Ohtsuka","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2022.01.034_bib67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiw500","article-title":"First-in-Human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus-vectored HIV type 1 gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens","volume":"215","author":"Nyombayire","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib68","first-page":"163","article-title":"Single-cycle adenovirus vectors in the current vaccine landscape","volume":"17","author":"Barry","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/hum.2014.016","article-title":"Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation","volume":"25","author":"Coughlan","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.01.034_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6030081","article-title":"Progress in adenoviral capsid-display vaccines","volume":"6","author":"Vujadinovic","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib71","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1016\/j.vaccine.2019.07.095","article-title":"Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice","volume":"37","author":"Asthagiri Arunkumar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib72","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/cid\/ciz653","volume":"70","author":"Cicconi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib73","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3389\/fimmu.2019.02005","article-title":"Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 antigens protects ferrets against influenza virus challenge","volume":"10","author":"McMahon","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib74","doi-asserted-by":"crossref","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib75","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib76","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib77","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib78","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/mt.2016.83","article-title":"Safety and immunogenicity of Chad63 and MVA ME-TRAP in West African children and infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.01.034_bib79","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3389\/fimmu.2017.01551","article-title":"Safety and immunogenicity of malaria vectored vaccines given with routine expanded program on immunization vaccines in Gambian infants and neonates: a randomized controlled trial","volume":"8","author":"Mensah","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib80","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ymthe.2022.01.034_bib81","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T\u00a0cell counts >350 cells\/mm(3)","volume":"33","author":"Churchyard","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib82","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib83","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.vaccine.2017.04.026","article-title":"Spray dried human and chimpanzee adenoviral-vectored vaccines are thermally stable and immunogenic in\u00a0vivo","volume":"35","author":"Afkhami","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib84","doi-asserted-by":"crossref","first-page":"19ra12","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib85","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/vaccines9111249","article-title":"Stability of chimpanzee adenovirus vectored vaccines (ChAdOx1 and ChAdOx2) in liquid and lyophilised formulations","volume":"9","author":"Berg","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib87","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","author":"Afolabi","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib88","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib89","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(20)30016-5","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib90","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2022.01.034_bib91","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","author":"Ishola","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib92","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib93","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.01.034_bib94","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140794","article-title":"A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","volume":"131","author":"Matsuda","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.01.034_bib95","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and Lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib96","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1586\/14760584.2015.1083429","article-title":"Ebola virus vaccine: benefit and risks of adenovirus-based vectors","volume":"14","author":"Mennechet","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib97","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/cid\/ciw158","article-title":"Ebola virus disease complications as experienced by survivors in Sierra Leone","volume":"62","author":"Tiffany","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib98","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1473-3099(15)00489-2","article-title":"Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study","volume":"16","author":"Mattia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib99","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/438575a","article-title":"Fruit bats as reservoirs of Ebola virus","volume":"438","author":"Leroy","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.01.034_bib100","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2020.04.061","article-title":"Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: an evidence-based analysis","volume":"38","author":"Antonello","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.01.034_bib102","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib103","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib104","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.01.034_bib105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ebiom.2016.09.028","article-title":"Preventative vaccines for Zika virus outbreak: preliminary evaluation","volume":"13","author":"Kim","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib106","doi-asserted-by":"crossref","first-page":"e5308","DOI":"10.1371\/journal.pone.0005308","article-title":"Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine","volume":"4","author":"Richardson","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.01.034_bib107","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib108","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1128\/JVI.02864-12","article-title":"Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates","volume":"87","author":"Richardson","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib109","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1086\/520603","article-title":"Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice","volume":"196","author":"Patel","year":"2007","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/mp200392g","article-title":"A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and Guinea pigs","volume":"9","author":"Choi","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2022.01.034_bib111","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2015.01.001","article-title":"Intranasal immunization with an adenovirus vaccine protects Guinea pigs from Ebola virus transmission by infected animals","volume":"116","author":"Wong","year":"2015","journal-title":"Antivir. Res"},{"key":"10.1016\/j.ymthe.2022.01.034_bib112","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.omtm.2019.12.003","article-title":"Targeting antigen to the surface of EVs improves the in\u00a0vivo immunogenicity of human and non-human adenoviral vaccines in mice","volume":"16","author":"Bliss","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.01.034_bib113","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/22221751.2019.1644968","article-title":"Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques","volume":"8","author":"Yang","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.ymthe.2022.01.034_bib114","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.01.034_bib115","article-title":"A multi-filovirus vaccine candidate: co-expression of Ebola, Sudan, and Marburg antigens in a single vector","volume":"8","author":"Sebastian","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib116","doi-asserted-by":"crossref","first-page":"e1007564","DOI":"10.1371\/journal.ppat.1007564","article-title":"Complete protection of the BALB\/c and C57BL\/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine","volume":"15","author":"Rahim","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2022.01.034_bib117","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.297.6648.584","article-title":"A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy","volume":"297","author":"Price","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2022.01.034_bib118","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys","volume":"83","author":"Baize","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib119","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1016\/j.vaccine.2019.09.030","article-title":"Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley Guinea pigs","volume":"37","author":"Maruyama","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41541-021-00291-x","article-title":"ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects Guinea pigs against lethal Lassa virus challenge","volume":"6","author":"Fischer","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2022.01.011","article-title":"A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice","author":"Bliss","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.01.034_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau2710","article-title":"Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine","volume":"4","author":"Matsuda","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib123","doi-asserted-by":"crossref","first-page":"115ra112","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib124","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib125","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T\u00a0cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2019.03.008","article-title":"Vaccine platforms for the prevention of Lassa fever","volume":"215","author":"Purushotham","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2022.01.034_bib127","doi-asserted-by":"crossref","first-page":"e0006628","DOI":"10.1371\/journal.pntd.0006628","article-title":"Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge","volume":"12","author":"Zivcec","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib128","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1016\/j.vaccine.2017.05.031","article-title":"Development of vaccines against Crimean-Congo haemorrhagic fever virus","volume":"35","author":"Dowall","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","article-title":"Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity","volume":"100","author":"Bente","year":"2013","journal-title":"Antivir. Res"},{"key":"10.1016\/j.ymthe.2022.01.034_bib130","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02076-16","article-title":"Immunization with DNA plasmids coding for Crimean-Congo hemorrhagic fever virus capsid and envelope proteins and\/or virus-like particles induces protection and survival in challenged mice","volume":"91","author":"Hinkula","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib131","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/vbz.2015.1855","article-title":"Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but No protection in STAT1 knockout mice","volume":"15","author":"Kortekaas","year":"2015","journal-title":"Vector Borne Zoonotic Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib132","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/21645515.2015.1078045","article-title":"A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease","volume":"12","author":"Dowall","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2022.01.034_bib133","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.virusres.2009.11.009","article-title":"The complete genome analysis of Crimean-Congo hemorrhagic fever virus isolated in Turkey","volume":"147","author":"Ozdarendeli","year":"2010","journal-title":"Virus Res."},{"key":"10.1016\/j.ymthe.2022.01.034_bib134","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/viro.2001.1133","article-title":"A lethal disease model for hantavirus pulmonary syndrome","volume":"289","author":"Hooper","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2022.01.034_bib135","first-page":"eabl6502","article-title":"Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies","volume":"375","author":"Mishra","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.01.034_bib136","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.cell.2021.05.001","article-title":"Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever","volume":"184","author":"Fels","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.01.034_bib137","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02005-19","article-title":"Structure and characterization of Crimean-Congo hemorrhagic fever virus GP38","volume":"94","author":"Mishra","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib138","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1128\/JVI.00373-09","article-title":"Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus","volume":"83","author":"Safronetz","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib139","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3892\/ijmm.2013.1421","article-title":"Induction of Hantaan virus-specific immune responses in C57BL\/6 mice by immunization with a modified recombinant adenovirus containing the chimeric gene, GcS0.7","volume":"32","author":"Li","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib140","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3201\/eid1112.050501","article-title":"Person-to-person transmission of Andes virus","volume":"11","author":"Martinez","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib141","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/vim.2005.18.657","article-title":"Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these","volume":"18","author":"Maeda","year":"2005","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib142","doi-asserted-by":"crossref","first-page":"eaau9812","DOI":"10.1126\/sciadv.aau9812","article-title":"Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection","volume":"4","author":"McMillen","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.01.034_bib143","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01394-19","article-title":"Rift Valley fever: a threat to pregnant women hiding in plain sight?","volume":"95","author":"McMillen","year":"2021","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib144","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/CVI.00182-09","article-title":"A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity","volume":"16","author":"Holman","year":"2009","journal-title":"Clin. Vaccine Immunol"},{"key":"10.1016\/j.ymthe.2022.01.034_bib145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-019-0138-0","article-title":"Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats","volume":"4","author":"Stedman","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib146","doi-asserted-by":"crossref","first-page":"101669","DOI":"10.1016\/j.isci.2020.101669","article-title":"Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein","volume":"23","author":"Wright","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2022.01.034_bib147","article-title":"Current status of Rift Valley fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib148","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2022.01.034_bib149","doi-asserted-by":"crossref","first-page":"16756","DOI":"10.1038\/srep16756","article-title":"Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice","volume":"5","author":"Dicks","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.01.034_bib150","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.01.034_bib151","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMra1808246","article-title":"Zika virus infection - after the pandemic","volume":"381","author":"Musso","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib152","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/JVI.02950-14","article-title":"Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors","volume":"89","author":"Abbink","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib153","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.01.034_bib154","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors","volume":"9","author":"Lopez-Camacho","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.01.034_bib155","doi-asserted-by":"crossref","first-page":"13097","DOI":"10.1128\/JVI.76.24.13097-13100.2002","article-title":"Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein","volume":"76","author":"Beasley","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib156","article-title":"Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines","volume":"8","author":"Lopez-Camacho","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib157","doi-asserted-by":"crossref","first-page":"e0202820","DOI":"10.1371\/journal.pone.0202820","article-title":"Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge","volume":"13","author":"Cox","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.01.034_bib158","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chom.2016.12.010","article-title":"Mapping and role of the CD8(+) T\u00a0cell response during primary Zika virus infection in mice","volume":"21","author":"Elong Ngono","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.01.034_bib159","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in\u00a0vivo and maintain activated CD8+ T\u00a0cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.01.034_bib160","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T\u00a0cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.01.034_bib161","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib162","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2214-109X(16)30367-9","article-title":"Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"5","author":"Li","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ymthe.2022.01.034_bib163","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib164","article-title":"Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study","author":"Sadoff","year":"2021","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib165","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged >\/=60 years","volume":"222","author":"Williams","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib166","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate middle east respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib167","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.01.034_bib168","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib169","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-017-0029-1","article-title":"Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model","volume":"2","author":"Munster","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib170","doi-asserted-by":"crossref","first-page":"16292","DOI":"10.1038\/s41598-019-52730-4","article-title":"Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels","volume":"9","author":"Alharbi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.01.034_bib171","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) covid-19 vaccine","author":"Falsey","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib172","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijid.2021.07.052","article-title":"Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia","volume":"110","author":"Al Bahrani","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib173","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib174","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib175","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib176","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib177","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib178","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib179","doi-asserted-by":"crossref","first-page":"21464","DOI":"10.1038\/s41598-021-00963-7","article-title":"Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran","volume":"11","author":"Babamahmoodi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.01.034_bib180","first-page":"408","article-title":"Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina","volume":"81","author":"Pagotto","year":"2021","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib181","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib182","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib183","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.01.034_bib184","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Garcia","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.01.034_bib185","doi-asserted-by":"crossref","first-page":"102662","DOI":"10.1016\/j.jaut.2021.102662","article-title":"Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection","volume":"121","author":"McGonagle","year":"2021","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.ymthe.2022.01.034_bib186","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib187","doi-asserted-by":"crossref","first-page":"n1114","DOI":"10.1136\/bmj.n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"Pottegard","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2022.01.034_bib188","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2022.01.034_bib189","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib190","doi-asserted-by":"crossref","first-page":"101061","DOI":"10.1016\/j.eclinm.2021.101061","article-title":"Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases","volume":"39","author":"Taquet","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib191","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1161\/STROKEAHA.121.035613","article-title":"Cerebral vein thrombosis with vaccine-induced immune thrombotic thrombocytopenia","volume":"52","author":"Siegler","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.ymthe.2022.01.034_bib192","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(21)01608-1","article-title":"Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study","volume":"398","author":"Perry","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib193","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barre syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib194","doi-asserted-by":"crossref","DOI":"10.3201\/eid2712.211634","article-title":"Guillain-barre syndrome associated with COVID-19 vaccination","volume":"27","author":"Shao","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib195","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/S0140-6736(20)32156-5","article-title":"Use of adenovirus type-5 vectored vaccines: a cautionary tale","volume":"396","author":"Buchbinder","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib196","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib197","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib198","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","article-title":"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study","volume":"14","author":"Gray","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib199","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (step study)","volume":"206","author":"Duerr","year":"2012","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib200","doi-asserted-by":"crossref","first-page":"e0136626","DOI":"10.1371\/journal.pone.0136626","article-title":"Effect of rAd5-vector HIV-1 preventive vaccines on HIV-1 acquisition: a participant-level meta-analysis of randomized trials","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.01.034_bib201","doi-asserted-by":"crossref","first-page":"e0137666","DOI":"10.1371\/journal.pone.0137666","article-title":"Continued follow-up of Phambili phase 2b randomized HIV-1 vaccine trial participants supports increased HIV-1 acquisition among vaccinated men","volume":"10","author":"Moodie","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.01.034_bib202","doi-asserted-by":"crossref","first-page":"19940","DOI":"10.1073\/pnas.0907898106","article-title":"Adenovirus vector vaccination induces expansion of memory CD4 T\u00a0cells with a mucosal homing phenotype that are readily susceptible to HIV-1","volume":"106","author":"Benlahrech","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.01.034_bib203","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1084\/jem.20081786","article-title":"Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T\u00a0cells","volume":"205","author":"Perreau","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib204","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nm.1991","article-title":"Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans","volume":"15","author":"O'Brien","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib205","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/infdis\/jis285","article-title":"Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials","volume":"205","author":"Stephenson","year":"2012","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib206","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAD.0b013e328342115c","article-title":"Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study","volume":"25","author":"Curlin","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.ymthe.2022.01.034_bib207","article-title":"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines","author":"Naranbhai","year":"2021","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.01.034_bib208","article-title":"Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants","author":"van Gils","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.01.034_bib209","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib211","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib212","article-title":"Effectiveness of the single-dose Ad26.COV2.S COVID vaccine","author":"Polinski","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.01.034_bib213","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021","volume":"70","author":"Self","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.ymthe.2022.01.034_bib214","article-title":"Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an omicron COVID19 wave: preliminary results of the Sisonke 2 study","author":"Gray","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.01.034_bib215","article-title":"Durability of protection against COVID-19 breakthrough infections and severe disease by vaccines in the United States","author":"Zheutlin","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.01.034_bib216","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.01.034_bib217","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2022.01.034_bib218","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib219","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.01.034_bib220","article-title":"Heterologous SARS-CoV-2 booster vaccinations - preliminary report","author":"Atmar","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.01.034_bib221","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib222","article-title":"Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients","author":"Kim Huat","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.01.034_bib223","doi-asserted-by":"crossref","first-page":"100372","DOI":"10.1016\/j.xcrm.2021.100372","article-title":"A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice","volume":"2","author":"Khan","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2022.01.034_bib224","doi-asserted-by":"crossref","first-page":"109452","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","author":"Hassan","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2022.01.034_bib225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.01.034_bib226","doi-asserted-by":"crossref","first-page":"e008748","DOI":"10.1136\/bmjopen-2015-008748","volume":"5","author":"Green","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymthe.2022.01.034_bib227","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jinf.2019.02.003","article-title":"Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults","volume":"78","author":"Green","year":"2019","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.ymthe.2022.01.034_bib228","article-title":"Safety and immunogenicity of a novel intranasal influenza vaccine (NasoVAX): a phase 2 randomized, controlled trial","volume":"9","author":"Tasker","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.01.034_bib229","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41586-021-03792-w","article-title":"After the pandemic: perspectives on the future trajectory of COVID-19","volume":"596","author":"Telenti","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.01.034_bib230","doi-asserted-by":"crossref","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.01.034_bib231","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","article-title":"Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors","volume":"116","author":"Alba","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.01.034_bib232","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ymthe.2020.10.002","article-title":"Pros and cons of adenovirus-based SARS-CoV-2 vaccines","volume":"28","author":"Kremer","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.01.034_bib233","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1016\/S2214-109X(21)00140-6","article-title":"Operation warp speed: implications for global vaccine security","volume":"9","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ymthe.2022.01.034_bib234","doi-asserted-by":"crossref","first-page":"m4750","DOI":"10.1136\/bmj.m4750","article-title":"Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis","volume":"371","author":"So","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2022.01.034_bib235","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","article-title":"Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)","volume":"398","author":"Flaxman","year":"2021","journal-title":"Lancet"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162200034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162200034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:04:36Z","timestamp":1761501876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162200034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":235,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S152500162200034X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.034","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenovirus-based vaccines\u2014a platform for pandemic preparedness against emerging viral pathogens","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}